the red report.

  • 12 04
    2019

    The Law Firm COO: Their Past Experience, Present Roles and a Look toward the Future

    Over the course of our firm’s 35-year history, we have conducted nearly 800 operational, financial and administrative leadership searches for law firms—large and small, regional and global. During this time, law firms’ top business leadership position has become increasingly more strategic and global.

    The Chief Operating Officer (or Executive Director, as the firm may title its top business leader) is responsible for managing the business operations of the firm. Interestingly, we have recruited ...

    MORE >
  • 11 22
    2019

    Our Guide to Surviving Thanksgiving’s Mishaps, Mayhem and Awkward Moments

    As Thanksgiving week approaches, it is time to reflect on our many blessings both personally and professionally. Over the years I’ve shared that Thanksgiving is my favorite holiday, I’ve reflected on the gauntlet of travelling during the busiest day for air travel, and polled our team on their favorite Thanksgiving foods.

    This year, acknowledging the less blessed moments of family gatherings, I asked the team at The Alexander Group and our sister firm ...

    MORE >
  • 11 13
    2019

    Harvard Grad, Working Mom and C-Suite Executive Wants Women in Science to Look at Her and Say, “I Can Do That Too”

    To celebrate our 35-year history in executive search, The Alexander Group and Alex & Red are reaching out to a several of the outstanding candidates we’ve recruited. This month, we interviewed Kate Haviland, Chief Operating Officer at Blueprint Medicines.

    Kate brings an impressive breadth of experience within the biopharmaceutical industry, encompassing business development, commercial and strategic planning, and program management. Kate joined Blueprint Medicines as Chief Business Officer in 2016, and assumed the COO role ...

    MORE >
  • 11 06
    2019

    Part 2: Two-time Life Sciences CEO Challenges Aspiring Leaders to Rethink Success

    This week, we continue our interview with Mike Bonney. As former CEO and Director of Cubist Pharmaceuticals culminating in the company’s acquisition by Merck for $9.4 billion, Mr. Bonney divides his time serving as board chair or board member of numerous biopharma companies and top academic institutions, giving a tremendous amount back to the greater community, as well as advising the next generation of leaders.

    Beth Ehrgott, a colleague at our sister firm ...

    MORE >